Skip to main content
Quest Diagnostics

Immunocompetent and Immunocompromised Cancer Populations: Post-vaccination Humoral and Cellular Immune Responses Against SARS-CoV-2

American Society of Clinical Oncology

ASCO 2023

Chicago, IL, June 2-6 , 2023

Published abstract: Immunocompetent and immunocompromised cancer populations: Post-vaccination humoral and cellular immune responses against SARS-CoV-2

Authors:  Titova E, Kan VW, Ip A, Lozy T, Shier K, Prakash VP, Starolis M, Ansari S, Goldgirsh K, Kim S, Pelliccia MC, Mccutchen A, Megalla M, Gunning TS, Kaufman HW,  Meyer WA, Perlin DS

Specialty: Oncology, Prescription Drug Monitoring, Toxicology, Infectious Disease, COVID-19

Conference Presentation
Evaluation of the Grifols Procleix® SARS-CoV-2 Assay for Donor Testing
Conference Presentation
Correlates of immunity in SARS-CoV-2 post-vaccine infectious in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study
Audio Podcast
Optimize Oncology Care with Clinical Pathways
On-Demand Webinar
Innovations within Precision Oncology Evolution of a Biomarker a Case Study of KRAS-G12C
On-Demand Webinar
Hypercoagulable State Associated With COVID-19 Infection

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.